Frontlight ResearchEarly access
CompletedNo phase
Clinical Trial of Type II Collagen vs. Sodium Hyaluronate Intra-articular Injection in Knee Osteoarthritis
Key facts
- Who runs it
- ATEMs
- Where
- South Korea4 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 117 people enrolled
- Started
- 27 Oct 2025
- Ended
- 9 Sept 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- CartiSave
- Hyalforte Injection
- Record updated
- 30 October 2026
Who can take part
- Age
- 19 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- 1. Adults aged 19 years or older
- 2. Patients who agreed to participate in the study and signed the informed consent form
- 3. Patients whose target knee joint intended for investigational product injection meet all of the following conditions at the screening visit:; 1) Knee joint pain due to Osteoarthritis; 2) Kellgren-Lawrence (K-L) Grade I to III confirmed by X-ray examination; 3) 100 mm Visual Analogue Scale (VAS) pain score of 40mm or higher during activity; 4) Absence of significant pathological findings, such as tumors
- 4. Patients who agree to use medically acceptable methods of contraception throughout the clinical trial period
Who cannot take part
- 5. Patients who use corticosteroids as follows at the screening visit:; 1) intra-articular injection at the target knee within 3 months; 2) systemic drug use within 3 months; 3) intra-articular injection at a joint other than the target knee within 4 weeks; 4) topical use is permitted except the target knee
- 6. Patients who have received analgesics or anti-inflammatory drugs within 48 hours prior to the screening visit
- 8. Patients who have participated in other interventional studies within 30 days prior to the screening visit
- 1. Patients with a known hypersensitivity or history of allergic reactions to the active substance or any components of the investigational medical device or comparator drug (e.g., porcrine-derived proteins)
- 2. Patients or their family members with autoimmune diseases
- 4. Patients with any of the following medical history or conditions at the screening visit:; 1) History of radiation therapy or cancer treatment within 2 years; 2) Severe knee trauma, surgery, or injection in the knee within 6 months that makes knee evaluation difficult; 3) Gout or calcium pyrophosphate deposition disease with onset within 6 months; 4) Severe intra-articular effusion; 5) Infectious disease requiring hospitalization for the administration of antibiotics; 6) Clinically significant, medically uncontrolled disease that may interfere with the study (e.g., hepatic, cardiac, renal, oncologic, diabetic, or psyshiatric disorders)
- 3. Patients with inflammatory arthritis such as rheumatoid arthritis, lupus arthritis, or psoriatic arthritis
- 7. Patients who are pregnant, breastfeeding, or planning to become pregnant during the trial
- 9. Patients who are considered inappropriate for participation in this study based on the investigator's judgement
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of this clinical trial is to evaluate the efficacy and safety of CartiSave compared with sodium hyaluronate in patients with knee pain.
The 2 groups in the trial
- CartiSave (2mL)Treatment being tested
Treatment: CartiSave
- Sodium Hyaluronate(2mL)Existing treatment, for comparison
Treatment: Hyalforte Injection
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multicenter, Randomized, Single-blind, Active-controlled, Parallel Clinical Trial to Evaluate the Efficacy and Safety of 'CartiSave' in Patients With Knee Joint Pain
- Record updated
- 30 October 2026